All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
During the ASCO 2022 Congress, the Multiple Myeloma Hub was pleased to speak to Roberto Mina, University of Turin, Turin, IT, and Andrzej J. Jakubowiak, The University of Chicago, Chicago, US. We asked, What are the pros and cons of bispecific antibodies for multiple myeloma?
What are the pros and cons of bispecific antibodies for multiple myeloma?
Mina and Jakubowiak discuss the MajesTEC-1 and MagnetisMM-1 trials, the efficacy and response rates of bispecific antibodies, and the challenges of using bispecific antibodies, such as infection risk. They also compare bispecific antibodies to CAR T-cell therapies and talk about the sequencing of therapies in myeloma treatment.
This educational resource is supported through funds from pharmaceutical companies; a full list of our supporters can be found at https://multiplemyelomahub.com/. All content is developed independently by SES in collaboration with the faculty. The funders are allowed no influence on the content of this resource.
Integrating BCMA-directed agents in the treatment landscape for relapsed/refractory MM
During a meeting of the Multiple Myeloma Hub Steering Committee on April 26, 2022, María‑Victoria Mateos chaired a recorded discussion that also featured Nina...
Findings from the MagnetisMM-1 trial of elranatamab in patients with RRMM: An update from ASH 2021
Elranatamab (PF-06863135) is a bispecific antibody (IgG2a) targeting the B-cell maturation antigen (BCMA) on multiple myeloma (MM) cells and CD3 on T...
Teclistamab, a BCMA/CD3 bispecific antibody for patients with RRMM: Phase I MajesTEC-1 trial results
Multiple myeloma remains an incurable disease despite recent advances in treatment, and so patients may undergo multiple rounds of remission and...
Subscribe to get the best content related to multiple myeloma delivered to your inbox